Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Executive Summary
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
You may also be interested in...
Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales
Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales
Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Novartis' decision to expand its sales force by 1,000 reps in the U.S. - in the face of cuts by many of its competitors - reflects the growth potential of the firm's product portfolio and the strength of its pipeline, Pharmaceuticals CEO Thomas Ebeling said